Nanotechnology in Drug Development and Life Cycle Management

  • Shingai Majuru
  • Moses O. Oyewumi
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume X)


Nanotechnology deals with the design, production, characterization and application of sub-micron-sized particles. The popularity and effectiveness of small-sized particles can be extended to broad areas in pharmaceutical, medical, chemical and engineering applications mainly due to their unique properties. The recognition for nanotechnology is well expressed by a great funding of US$1.28 billion to the US National Nanotechnology Initiative (NNI) for the fiscal year 2007.1 Also, it is estimated that the drug market for nanotechnology could be worth as much as US$200 billion by 2015 (Breen, 2006). Examples of nanoparticulate drug carriers are liposomes, microemulsions, nanosuspensions and nanoparticles (Mumper, Cui & Oyewumi, 2003). These systems can be formulated into a variety of dosage forms including parenteral, tablets, hard gelatin capsules, soft gelatin capsules and oral liquid dosage forms. In many studies, nanoparticulate carriers have been demonstrated as...


Drug Release Drug Product Emulsion Polymerization Nanoparticle Formulation Solid Lipid Nanoparticles 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Agostiano, A., Catalano, M., Curri, M.L. Della, Monica, M., Manna L., Vasanelli, L. (2000) Synthesis and structural characterization of CDs nanoparticles prepared in four-components “water-in-oil”. microemulsion. Micron. 31, 253–258CrossRefGoogle Scholar
  2. Allènmann, E., Gurny, R., Doelker, E. (1993) Drug-loaded nanoparticles-preparation methods and drug targeting issues. Eur. J. Biopharm. 39, 173–191.Google Scholar
  3. Attwood, D. (1994) Microemulsions. In: J Kreuter (eds) Colloidal drug delivery. New York Marcel DekkerGoogle Scholar
  4. Breen, P.V. (2006) Small-tech big potential. Drug Deliv, November 2006, 30–31Google Scholar
  5. Brigger, I., Dubernet, C., Couvreur, P. (2002) Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631–651CrossRefGoogle Scholar
  6. Dearn, A.R. (1995) Atovaquone pharmaceutical compositions. European patent EU 0/075711, August 5Google Scholar
  7. Delie, F., Blanco-Prieto, M.J. (2005) Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10, 65–80.CrossRefPubMedGoogle Scholar
  8. Desai, M.P., Labhasetwar, V., Walter, E., Levy, R.J., Amidon, G.L. (1997) The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14, 1568–1573CrossRefPubMedGoogle Scholar
  9. Fang, J., Stokes, K.L., Wiemann, J., Zhou, W. (2000) Nanocrystalline bismuth synthesized via an in situ polymerization microemulsion process. Mater. Lett. 42, 113–120CrossRefGoogle Scholar
  10. Fahmy, T. M. Fong, P.M. Goyal, A., Saltzman, W.M. (2005) Targeted for drug delivery. Nanotoday, August, 18–26Google Scholar
  11. Fendler, J.H. (1994) Membrane-mimetic approach to advanced materials. In Advances in Polymer Science 113, Springer BerlinGoogle Scholar
  12. Feng, S. (2004) Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev. Med Devices 1, 115–125CrossRefPubMedGoogle Scholar
  13. Freitas, C., Muller, R.H. (1998) Spray-drying of solid lipid nanoparticles. Eur. J. Pharm and Biopharm. 46, 145–151CrossRefGoogle Scholar
  14. Gasco, M.R. (1997) Solid lipid nanospheres from warm microemulsions. Pharm. Tech. Eur. 9, 52–58Google Scholar
  15. Huettenrauch, R. (1984) Molecular pharmaceutics. Part 86. Stability of activated states in solid drug forms. Pharmazie 39, 272Google Scholar
  16. Hu, J., Johnston, K.P., Williams, R.O. (2004) Nanoparticle engineering process for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind. Pharm. 30, 233–245CrossRefPubMedGoogle Scholar
  17. Jung, T., Kamm, W., Bretenbach, A., Kaiserling, E., Xiao, J.X., Kissel, T. (2000) Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharma. Biopharm. 50, 147–160CrossRefGoogle Scholar
  18. Kayser, O., Lemke, A., Hernandez-Trejo, N. (2005) The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotech. 6, 3–5Google Scholar
  19. Kim, G., Nie, S. (2005) Targeted cancer nanotherapy. Nanotoday 28–33Google Scholar
  20. Kipp, J.E. (2004) The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284, 109–122CrossRefPubMedGoogle Scholar
  21. Knight, P. (2006) Transforming potential for difficult drugs. Drug Delivery, November 2006, 6–8Google Scholar
  22. Landfester, K. (2001) Polyreactions in miniemulsions Macromol. Rapid Commun. 22, 896–936CrossRefGoogle Scholar
  23. Langevin, D. (1991) Microemulsions-interfacial aspects Adv Colloid Interface Sci. 34: 583CrossRefGoogle Scholar
  24. Liversidge, G.G., Cundy, K.C. (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. Int. J. Pharm. 125, 91–97CrossRefGoogle Scholar
  25. Lockman, P.R., Mumper, R.J., Khan, M.A., Allen, D.D. (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm. 28.Google Scholar
  26. Mehnert, W., Mader, K. (2001) Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Del. Rev 47, 165–196CrossRefGoogle Scholar
  27. Muller, R.H. Jacobs, C., Kayser, O. (2001) Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3–19CrossRefGoogle Scholar
  28. Mumper, R.J. Cui, Z., Oyewumi, M.O. (2003) Nanotemplate engineering of cell-specific nanoparticles. J. Disp. Sci. Tech. 24, 569–588CrossRefGoogle Scholar
  29. Moghimi, S.M., Hunter, A.C. (2001) Capture of stealth nanoparticles by body defences. Crit. Rev. Ther. Drug Carrier Sys. 6, 527–550Google Scholar
  30. Oyewumi, M.O., Mumper, R.J. (2002) Gadolinium loaded nanoparticles engineered from microemulsion templates. Drug Dev. Ind. Pharm. 28, 317–328CrossRefPubMedGoogle Scholar
  31. Panchapakesan, B. (2005) Nanotechnology: Part 2 Tiny Technology-tremendous therapeutic potential. Oncology Issues Nov/Dec 2005Google Scholar
  32. Pikal, M.J. Shah, S., Roy, M.L., Putman, R. (1990) The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. Int. J. Pharm. 60, 203–217CrossRefGoogle Scholar
  33. Rabinow, B.E. (2004) Nanosuspensions in drug delivery. Nat. Rev Drug Discov. 3, 785–796.CrossRefGoogle Scholar
  34. Schmidt, C., Bodmeier, R. (1999) Incorporation of polymeric nanoparticles into solid dosage forms. J. Control. Rel. 57, 115–125CrossRefGoogle Scholar
  35. Setler, 1995, P. (1999) Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. IIR Limited Drug Delivery Systems, London, March 1999Google Scholar
  36. Sham, J.O., Zhang, Y., Finlay, W.H., Roa, W.H., Lobenberg, R. (2004) Formulation and characterization for aerosol delivery to the lung. Int. J. Pharm. 269, 457–567CrossRefPubMedGoogle Scholar
  37. Ward, G.H., Schultz, R.K. (1995) Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. Pharm. Res. 12, 773–779CrossRefPubMedGoogle Scholar
  38. Wissing, S.A., Muller, R.H. (2003) Cosmetic applications for solid lipids nanoparticles (SLN). Int. J. Pharm. 254, 65–68CrossRefPubMedGoogle Scholar
  39. Wu, N.Z. Da, D., Rudoll, T.L., Needham, D. Whorton, A.R. Dewhirst, M.W. (1993) Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53, 3765–3770PubMedGoogle Scholar
  40. Yi, Y.M., Yang, T.Y., Pan W.M. (1999) Preparation and distribution of 5-fluorouracil I-125 sodium alginate-bovine serum albumin nanoparticles. World J. Gastroenterol. 5, 57–60PubMedGoogle Scholar
  41. Yoo, H.S. Lee, K.H. Oh, J.E., Park, T.G. (2000) In vitro and in vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Control. Rel. 68, 419–431CrossRefGoogle Scholar
  42. Zuidam, N.J., Lee, S.S.L., Crommelin, D.J.A. (1992) Sterilization of liposomes by heat treatment. Pharm. Res. 10, 1591–1596Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Shingai Majuru
    • 1
  • Moses O. Oyewumi
    • 1
  1. 1.Department of Pharmaceutics Research and DevelopmentEmisphere Technologies, IncTarrytownUSA

Personalised recommendations